The Biggest Challenges in US DTC Pharmaceutical Advertising

DTC teams rarely fail because of one big problem. They fail because five medium problems stack up: a slow review cycle eats the launch window, the audience gets narrowed by privacy review, the buy shifts to cheap reach to hit the plan, and the outcome data arrives too late to fix any of it. Below are the seven challenges that show up most in US programs, with what to do about each. For the wider context, see the DTC pharma marketing guide.

1. Regulatory scrutiny of drug ads is rising

In September 2025, FDA announced it was sending thousands of letters to drug companies, about 100 cease-and-desist letters over ads it considered deceptive, and starting rulemaking to remove the "adequate provision" approach that lets broadcast ads point to other sources for full risk information. If that rulemaking goes through, broadcast and streaming spots may need to carry more risk content directly. Check the current status, since it may have moved since this was written.

What to do: bring regulatory reviewers into concept development rather than final review. Build a library of pre-approved risk modules by format and length. Read recent OPDP letters as a team, because they show what reviewers object to in practice. And speed up the review process itself; faster MLR approvals for programmatic media has specific steps.

2. TV costs rise while linear reach falls

Linear TV still delivers scale, but each year it reaches fewer people for roughly the same or more money. Pharma spots tend to run long because of the major statement, which makes each placement expensive.

What to do: treat linear and CTV as one video budget and plan to deduplicated reach rather than channel by channel. Shift share to streaming where your audience has moved, but keep enough linear to protect reach among older viewers if your condition skews that way. The tradeoff is covered in linear TV vs. CTV for pharma DTC.

3. Privacy limits on health targeting

NAI rules generally require opt-in consent for targeting based on sensitive health conditions. Washington's My Health My Data Act, and similar laws in a few other states, regulate consumer health data broadly, including inferences. Platforms have also restricted health-based targeting on their own. The result: the precise condition audiences that DTC teams used to buy are smaller, more expensive, or unavailable.

What to do: classify the condition by sensitivity first. For sensitive conditions, default to contextual and broad audiences. For less sensitive ones, run vendor due diligence on consent and provenance before you buy. State-by-state detail is in state consumer health data laws and pharma media.

4. Outcome measurement arrives late

Prescription outcomes depend on claims or pharmacy data that lag media by weeks to months, plus the time it takes a patient to book an appointment and fill. A brand may see its first credible read on new-to-brand starts a full quarter after launch.

What to do: agree on leading indicators that have shown some relationship to outcomes in past reads (qualified site visits, discussion guide downloads, savings card activations), and use them for in-flight decisions. Set up a holdout or matched market design at launch so the late outcome read is also an incremental one. Vendor selection is covered in how to choose a DTC measurement platform.

5. Streaming supply is fragmented

Your CTV impressions are spread across many apps, devices, and resellers. Frequency gets out of control because no single platform sees the whole household, and some supply is resold through paths that add fees without adding quality.

What to do: cap frequency at the household level where your stack allows it, buy through direct deals or curated PMPs for the bulk of spend, and audit the supply chain with ads.txt and sellers.json. Ask for app-level reporting and remove apps that do not belong on a pharma plan.

6. Low consumer trust and creative boxed in by fair balance

Trust

Many viewers are skeptical of drug advertising, and the public debate in 2025 made that more visible. Spots that look like every other pharma spot (lifestyle footage, upbeat music, rapid risk voiceover) tend to blend together.

What to do: lean on specific, useful information: what the condition is, what to ask a doctor, what support exists. Help-seeking and condition education content often earns more attention than product claims, and it is easier to place in trusted health publishers.

Creative constraints

Risk information takes up a large share of every spot, banner, and post. In small formats, there is little room left for the benefit message.

What to do: design formats around the risk content instead of fitting it in at the end. Use longer video where the story needs it, scrolling ISI in display, and click-through to full information. On social and search, test whether the platform can hold balanced content at all; FDA's 2014 draft guidance on character-limited platforms says that if it cannot, reconsider the platform.

A summary table you can bring to planning

For how these responses shape the actual channel split, see pharmaceutical DTC media strategy.

Practical takeaway

Pick the two challenges from the table that hurt your brand most last year and assign each a named owner and a fix due before the next plan is approved. For most teams, one of the two should be measurement lag, with a holdout design agreed before any media is bought.

Frequently asked questions

What is the biggest challenge in DTC pharma advertising right now?

Regulatory scrutiny is the most visible, after FDA's September 2025 actions on drug ads. For day-to-day planning, measurement lag is often the more damaging problem, because weak tactics can run for months before outcome data shows they are not working.

Why is DTC pharma advertising so expensive?

Fair balance requirements push broadcast spots to longer lengths, linear TV prices have stayed high while audiences shrink, and health audiences carry data and compliance costs. Small conditions also force teams to pay for a lot of reach that lands outside the patient population.

Can pharma brands still target people by health condition?

Yes, within limits. Sensitive condition targeting generally needs opt-in consent under NAI rules, and state laws like Washington's My Health My Data Act add consent requirements for consumer health data. Many brands now use contextual targeting or broad demographic and interest audiences for sensitive conditions.

Sources

• FDA, FDA Launches Crackdown on Deceptive Drug Advertising (September 9, 2025)
• FDA, Office of Prescription Drug Promotion (OPDP)
• Washington State Office of the Attorney General, Protecting Washingtonians' Personal Health Data and Privacy
• Network Advertising Initiative

External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.